Max Portfolio Pct.
Check
Valuation
Check
Stock Quality:
Max Portfolio Pct.
Check
Valuation
Check
MNOV Price Action
Last 7 days
-1.6%
Last 30 days
-2.4%
Last 90 days
-3.1%
Trailing 12 Months
-36.9%
MNOV Stock Price
MNOV RSI Chart
MNOV Valuation
MNOV Price/Sales (Trailing)
The Good, Bad and Ugly
Growth
Profitability
Size
Dilution Risk
Balance Sheet
Momentum
Funds Popularity
Insider Trading
MNOV Fundamentals
MNOV Revenue
MNOV Earnings
MNOV Profitability
MNOV Investor Care
Revenue & Growth
Revenue Breakdown
As of: Jun 30, 2025
Reportable Aggregation Before Other Operating
| |||||||||||
| |||||||||||
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2025 | 0 | 0 | 0 | 0 |
| 2024 | 2.7M | 2.7M | 0 | 1.7M |
| 2023 | 1.3M | 1.6M | 2.4M | 2.8M |
| 2022 | 3.2M | 2.4M | 1.6M | 809.7K |
| 2021 | 7.4M | 8.7M | 9.9M | 4.0M |
| 2020 | 6.6M | 7.0M | 6.6M | 6.2M |
| 2019 | 1.7M | 1.7M | 1.8M | 6.5M |
| 2018 | 7.8M | 5.7M | 3.6M | 1.5M |
| 2017 | 2.6M | 5.0M | 7.5M | 9.9M |
| 2016 | 495.5K | 383.5K | 271.5K | 159.5K |
| 2015 | 2.9M | 2.1M | 1.4M | 607.5K |
| 2014 | 5.4M | 4.8M | 4.3M | 3.7M |
| 2013 | 3.4M | 0 | 0 | 6.0M |
| 2012 | 0 | 0 | 0 | 802.6K |
Get all data in R, Python etc through our Historical Stock Data APIs
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.
| CEO | Dr. Yuichi Iwaki M.D., Ph.D. |
|---|---|
| WEBSITE | medicinova.com |
| SECTOR | Healthcare |
| INDUSTRY | Biotechnology |
| EMPLOYEES | 13 |
